Zweig Di Menna Associates LLC Sigilon Therapeutics, Inc. Call Options Transaction History

Zweig Di Menna Associates LLC

  • $951 Million
  • Q3 2024

Call Options

0 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
No transaction found.

About Sigilon Therapeutics, Inc.

SGTX Quotes by TradingView
  • Ticker SGTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 32,399,300
  • Description
  • Sigilon Therapeutics, Inc., a clinical stage biotechnology company, develops functional cures for patients with chronic diseases. Its lead product candidate is SIG-001, which is in Phase I/II clinical trial to prevent bleeding episodes in patients with moderate to severe Hemophilia A. The company is also developing SIG-005 to treat the non-neuro...
More about SGTX
Track This Portfolio

Track Zweig Di Menna Associates LLC Portfolio

Follow Zweig Di Menna Associates LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Zweig Di Menna Associates LLC, based on Form 13F filings with the SEC.

News

Stay updated on Zweig Di Menna Associates LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email